In-Licensing Opportunity Assessment

A leading research-based international pharmaceutical company was interested in enhancing its present portfolio by in-licensing an asset and understand in detail available opportunities for a Phase-II asset. Based on the broader objectives and valid assumptions, FutureBridge built a robust business case for the Phase II product which they wish to in-license from another company, with key insights such as the addressable patient pools, market size, and key risks involved.